Mark S. Marshall, PhD, MS

Dedicated Cancer Research Professor with more than 28 years of experience in academia and the biotechnology industry. Driven professional recognized as a leader in the fields of Ras oncogene function, cell cycle and cancer genetics. Scientific leader with a proven career history of spearheading successful oncology drug programs while managing cross-disciplined research teams to deliver three clinical molecules. Visionary professional with a current focus on delivering precision medicine options to clinical pediatric oncologists. Driven leader directing high-profile academic collaborations, co-inventing 9 patents, and authoring more than 90 scientific papers, FDA study reports, and book chapters.

Barnard, D., Diaz, H., Burke, T., Donoho, G., Beckmann, R., Jones, B., Barda, D., King, C. and M. Marshall. 2016. LY2603618, a Selective CHK1 Inhibitor, Enhances the Anti-tumor Effect of Gemcitabine in Xenograft Tumor Models. Invest New Drugs. 34 (1):49-60.

King, C., Diaz, H., McNeely, S., Barnard, D., Dempsey, J., Blosser, W., Beckmann, R., Barda, D. and Marshall, M. 2015. LY2606368 causes replication catastrophe and anti-tumor effects through CHK1-dependent mechanisms. Mol Cancer Ther. 14 (9):2004-13.

King, C., Diaz, H., Barnard, D., Barda, D., Clawson, D., Blosser, W., Cox, K., Guo, S. and Marshall, M. 2013. Characterization and preclinical development of LY2603618: A selective and potent Chk1 inhibitor. Invest New Drugs. 32(2):213-26.